Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immunocore Holdings (IMCR) Non Operating Income (2023 - 2025)

Immunocore Holdings (IMCR) has disclosed Non Operating Income for 3 consecutive years, with $4.5 million as the latest value for Q4 2025.

  • Quarterly Non Operating Income rose 353.58% to $4.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $19.7 million through Dec 2025, up 38.95% year-over-year, with the annual reading at $19.7 million for FY2025, 38.95% up from the prior year.
  • Non Operating Income hit $4.5 million in Q4 2025 for Immunocore Holdings, down from $5.1 million in the prior quarter.
  • In the past five years, Non Operating Income ranged from a high of $9.0 million in Q3 2024 to a low of -$325000.0 in Q1 2023.
  • Historically, Non Operating Income has averaged $2.8 million across 3 years, with a median of $2.7 million in 2024.
  • Biggest five-year swings in Non Operating Income: soared 4767.71% in 2024 and later plummeted 43.52% in 2025.
  • Year by year, Non Operating Income stood at -$191000.0 in 2023, then skyrocketed by 619.9% to $993000.0 in 2024, then skyrocketed by 353.58% to $4.5 million in 2025.
  • Business Quant data shows Non Operating Income for IMCR at $4.5 million in Q4 2025, $5.1 million in Q3 2025, and $4.7 million in Q2 2025.